# Treatment of chronic constipation in the elderly – laxatives versus dietary and lifestyle changes

### Introduction

The aim of the HTA programme is to ensure that high quality research information on the costs, effectiveness and broader impact of health technologies is produced in the most efficient way for those who use, manage and work in the NHS. Questions are identified and prioritised to meet the needs of the NHS and its patients. Health technology assessment forms the largest portfolio of work in the NHS Research and Development Programme and each year about forty new studies are commissioned to help answer questions of direct importance to the NHS. The studies include primary and secondary research and cost about £10 million a year.

# Question

• What is the comparative cost-effectiveness of laxatives compared with dietary and lifestyle changes in the treatment of elderly patients with chronic constipation?

# The topic

Research is needed to evaluate these different interventions, and the cost to the NHS, in the community setting. Dietary and lifestyle interventions should be clearly defined. Dietary interventions should be differentiated from the use of bulk laxatives such as bran. Outcomes should include bowel function and quality of life. Research may compare single laxative agents with dietary and/or lifestyle changes.

## **Methods**

On this topic, primary research is required. For many of the questions posed by the HTA programme, a randomised controlled trial is likely to be the most appropriate method of providing an answer. However, there may be practical or ethical reasons why this might not be possible. Applicants proposing other research methods are invited to justify these choices.

The different interventions need to be evaluated in a study of sufficient power in the community setting. A factorial study design may be useful. Researchers are asked to consider and justify the appropriate duration of the study.

Applicants are required to comply with the Medical Research Council's Good Clinical Practice guidelines (www.mrc.ac.uk/clinical\_trials/ctg.html).

If you wish to submit an outline proposal on this topic, complete the electronic application form and return it to the Commissioning Manager at the National Co-ordinating Centre for Health Technology Assessment, Mailpoint 728 Boldrewood, University of Southampton, Southampton SO16 7PX by 11 May 2001. Outline applications will be considered by the HTA Commissioning Board at its meeting in July 2001. If they are acceptable, investigators will be given a minimum of eight weeks to submit a full proposal.

# Applications received after 1700 hours on the due date will not be considered.

j:\prioritisation\combrf2001\finaladvertmar2001cb\eld-constp-cb2-febpsglaxdiet.doc

15 February 2001

# **Guidance on applications**

# Required expertise

HTA is a multidisciplinary enterprise. It needs to draw on the expertise and knowledge of clinicians and of those trained in health service research methodologies such as health economics, medical statistics, study design and qualitative approaches. Applicants will need to show a commitment to team working and may wish to consider a collaborative approach between several institutions. It is expected that the research will be undertaken only following a thorough literature review.

## **Outcomes**

Wherever possible, the results of HTA should provide information about the effectiveness and costeffectiveness of care provided in its usual clinical setting and for the diverse subjects who would be
eligible for the interventions under study. The endpoints of interest will in most cases include disease
specific measures, health related quality of life and costs (directly and indirectly related to patient
management). Wherever possible, these measurements should be made by individuals who are
unaware of the treatment allocation of the subjects they are assessing. We encourage applicants to
involve consumers of health care in the preparation of their proposal, for instance in selecting patientoriented outcomes. A period of follow up should be undertaken which is sufficient to ensure that a
wider range of effects are identified other than those which are evident immediately after treatment.
These factors should guide applicants in their choice of subjects, settings and measurements made.

# Sample size

A formal estimate should be made of the number of subjects required to show important differences in the chosen primary outcome measure. Justification of this estimate will be expected in the application.

### Communication

Communication of the results of research to decision makers in the NHS is central to the HTA Programme. Successful applicants will be required to submit a single final report for publication by the HTA programme. They are also required to seek peer-reviewed publication of their results elsewhere and may also be asked to support the NCCHTA in further efforts to ensure that results are readily available to all relevant parties in the NHS. Where findings demonstrate continuing uncertainty, these should be highlighted as areas for further research.

## **Timescale**

There are no fixed limits on the duration of projects or funding and proposals should be tailored to fully address the problem. However, there is a pressing need within the NHS for the information and so the research would normally be expected to be completed within three years, unless long-term follow-up is necessary.